Compare Quest Diagnostics Inc (DGX) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Quest Diagnostics Inc trades at $230.65 (market cap $25.48B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.68 (market cap $1.45B). The key difference: Quest Diagnostics Inc is far larger — about 17.6× Direxion NASDAQ 100 Equal Weighted Index Shares's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Direxion NASDAQ 100 Equal Weighted Index Shares for 48 Days on average.
| DGX | QQQE | |
|---|---|---|
Market Cap | $25.48B | $1.45B |
Volume | 941,866 | 323,568 |
Sector | Health | Broad Market / Factor |
52-Week High | $247.45 | $124.69 |
52-Week Low | $173.49 | $96.06 |
Typical Hold Time | 56 Days | 48 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
QQQE (Direxion NASDAQ-100 Equal Weighted Index ETF) trades at $121.58, down 0.25% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF provides equal-weighted exposure to NASDAQ-100 companies, reducing technology concentration from 60% to 45% compared to market-cap weighted alternatives. Recent analysis suggests QQQE offers tactical advantages over QQQ for the next twelve months due to its equal-weight methodology.
The outlook for QQQE appears favorable as equal weighting provides diversification benefits amid potential tech sector volatility. Key risks include NASDAQ concentration and market sensitivity, but the ETF's structure offers balanced exposure to large-cap growth stocks. Technical support levels at $120-121 provide near-term downside protection.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
